National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Doxylamine/Pyridoxine (Xonvea®)

Doxylamine/pyridoxine (Xonvea®) is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.


NCPE Assessment Process Complete
Rapid review commissioned 23/07/2019
Rapid review completed 15/08/2019
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Xonvea®) not be considered for reimbursement at the submitted price*


* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.